Skip to main content
Premium Trial:

Request an Annual Quote

OpGen Raises Total of $20M in Series B Round

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm OpGen has raised a total of $20 million in its Series B financing round, to be used to advance commercialization of its platform for the generation of de novo whole genome restriction maps.

In a document filed with the US Securities and Exchange Commission this week, the Gaithersburg, Md.-based firm disclosed it had raised $11.9 million. According to a company spokesman, the funds raised include part of a $17 million Series B round announced in September and an additional $3 million, making the total raised in the B round $20 million.

The $17 million raised in September was led by jVen Capital and included participation from existing investors CHL Medical Partners, Highland Capital Partners, Mason Wells Biomedical, and Versant Ventures. The additional $3 million came from new investors, whom OpGen declined to identify.

The funds will be used for the continued commercialization of OpGen's Argus Optical Mapping System, which uses optical mapping technology for whole-genome sequence assembly and finishing. The system was launched in the spring.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.